NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Beone Medicines Ltd. ONC
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.3B
▲ 40.2% vs FY2024
EPS · FY25
$0.19
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
7.5%
Net margin · FY25
5.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.3B
Revenue, FY2025 · full 12-year series below
Revenue
Net income
5 cents of every revenue dollar became profit this year.
Per share
USD 0.19
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
7.5%
Return on equity, FY2025
ROE
Operating margin8.4%
Net margin5.4%
Return on assets4.1%
Each USD of equity produced 7 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+76.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+55.7%
+76.8%
+89.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
1.44B
Shares outstanding, FY2025
Change, 5 years+21.0%
Change, 10 years—
The share count grew 21% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.2B
total assets, end of FY2025
Total assetsUSD 8.2B
EquityUSD 4.4B
CashUSD 4.5B
Gross debtUSD 1.0B
Net debtUSD -3.5B
Current ratio3.41×
The company holds more cash than debt.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
5.3
3.8
2.5
1.4
1.2
0.3
0.4
0.2
0.2
0.0
0.0
0.0
Operating income $B
0.4
−0.6
−1.2
−1.8
−1.4
−1.7
−1.0
−0.7
−0.1
−0.1
−0.1
−0.0
EBITDA $B
0.6
−0.4
−1.1
−1.7
−1.4
−1.6
−0.9
−0.7
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
0.3
−0.6
−0.9
−2.0
−1.5
−1.6
−0.9
−0.7
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
0.19
−0.47
−0.65
−1.49
−1.21
−1.50
−1.22
−0.93
−0.17
−0.30
−0.52
−0.18
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
7.5
−18.8
−22.3
−38.1
−29.2
−67.3
−70.2
−55.9
−18.2
−94.9
·
·
Shares out B
1.44
1.39
1.36
1.36
1.33
1.19
0.80
0.78
0.59
0.52
0.12
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed